# DESCRIPTION

## BACKGROUND

### 1. Field of the Invention

- define field of invention

### 2. Background of the Invention

- introduce cancer statistics
- describe glioblastoma treatment resistance
- explain ferroptosis and glutathione
- discuss cancer cell metabolism
- highlight need for dietary approach
- identify need for convenient diet

## SUMMARY OF THE INVENTION

- introduce dietary formulation
- describe cysteine and methionine deprivation diet
- outline CMD formulation composition
- describe co-administration with radiotherapy
- describe promotion of iron ferroptosis
- describe co-administration with chemotherapeutic agent

## DETAILED DESCRIPTION

### 1. Definitions

- define technical terms
- explain meaning of "about"
- define ferroptosis
- define cancer therapy
- define cancer therapeutic agent
- define radiotherapy
- define subject
- define cysteine methionine deprivation (CMD) diet
- define CMD formulation
- define cysteine deprived-methionine restricted (CDMR) diet
- define therapy
- define administering
- define co-administration
- define ferroptosis
- define therapeutically effective amount

### 2. Overview

- introduce ferroptosis and its relation to cancer
- describe the effect of dietary restriction of cysteine and methionine on glioma

### 3. Summary of Results

- summarize effects of CMD in vitro
- summarize effects of CMD in vivo
- describe changes in lipid profiles
- summarize benefits of CMD diet

### 4. Embodiments of the Invention

- introduce formulations
- describe RSL3-mediated cell death
- describe synergistic effect of CMD and ferroptosis inducers
- describe in vivo dietary deprivation of cysteine and methionine
- describe dietary formulation and supplement
- describe restriction of sulfur-containing amino acids
- describe satiety of formulation
- describe applicability to other cancer types
- describe inert ingredients
- describe caloric density
- describe serving size
- describe constituents of formulation
- describe optional ingredients
- describe Table 1
- describe Table 2
- introduce methods of use
- describe providing dietary formulations
- describe consuming diet
- describe applicability to other cancer types
- describe disease states or conditions
- describe neurodegenerative disorders
- describe metabolic disorders
- describe benign tumors
- describe coefficient of drug interaction (CDI)
- describe synergistic effect
- describe regimen

### 5. Examples

- introduce example 1
- describe in vitro assays
- describe cell lines and culture conditions
- generate murine glioma cell lines
- describe culture media
- generate acute organotypic slice cultures
- describe real-time quantitative PCR primers
- describe real-time quantitative PCR method
- describe cell viability assays
- describe flow cytometric analysis
- describe slice cultures
- describe time-lapse confocal imaging
- describe extracellular flux analysis
- describe fatty acid oxidation assay
- describe animal models
- describe orthotopic tumor implantation
- describe diet allocation
- describe in vivo studies
- describe synergy assessment
- introduce experimental design
- describe anesthesia and surgical procedures
- detail tumor implantation and monitoring
- outline diet preparation and administration
- describe tissue collection and preservation
- detail targeted metabolomic profiling sample preparation
- describe in vitro sample preparation
- outline LC-MS data acquisition and processing
- detail global quantitative proteomics analysis
- describe protein digestion and peptide preparation
- outline mass spectrometry analysis
- detail data analysis and protein identification
- describe DESI-IMS tissue preparation
- outline DESI-IMS data acquisition and processing
- detail image analysis and statistical comparisons
- introduce example 2: CMD sensitizes glioma cells to ferroptosis induction
- describe media adaptation for cell culture
- detail responsiveness of glioma cell lines to ferroptosis induction
- describe live-cell confocal microscopy
- outline ferroptosis inhibitor testing
- detail dose response assays
- describe synergistic enhancement of ferroptosis with CMD
- outline increased sensitivity to RSL3 mediated ferroptosis by CMD
- detail AUC quantification for close response curves
- describe pre-treatment incubation of glioma cells in CMD
- outline Bodipy-C11 fluorescence shift analysis
- detail ex vivo organotypic slice culture model
- describe ROS level analysis using H2DCFDA
- summarize results
- introduce example 3
- investigate transcriptional hallmarks of ferroptosis
- analyze mRNA expression
- present RT-qPCR data
- show changes in CHAC1, PTGS2, SLC7a11, and ATF4 transcripts
- analyze ex vivo setting
- present RT-qPCR data for ex vivo organotypic slices
- show changes in CHAC1, SLC7a11, and ATF4 transcripts
- introduce example 4
- characterize effects of CMD on glioma cell metabolism
- perform targeted metabolite profiling
- analyze principal component analysis
- show enrichment ratio of metabolite pathways
- present heatmap of differentially assessed metabolites
- analyze glutathione levels
- show changes in citric acid cycle metabolites
- analyze top downregulated metabolites
- measure mitochondrial respiration
- analyze Seahorse Mitochondrial stress test
- introduce example 5
- test effects of dietary CMD on survival
- analyze Kaplan-Meier survival curve
- show changes in mouse weights
- introduce example 6
- analyze proteomic changes induced by CMD
- perform targeted metabolite profiling
- analyze joint pathway analysis
- perform mass spectrometry imaging experiment
- analyze DESI-MS images
- introduce example 7
- demonstrate lower levels of glutathione
- analyze effects of CMD on ferroptosis
- present example 9
- show serial luciferase imaging
- describe CMD treatment in combination with radiation
- present data on tumor growth rate
- present example 10
- show cell viability data
- describe CMD treatment and radiation
- present coefficient of drug interaction data
- present example 11
- outline in vivo experiments
- describe CMD and radiation treatment
- present survival data
- present example 12
- describe human diffuse astrocytoma slice cultures
- show synergy of radiation with IKE treatment
- present example 13
- describe radiation plus IKE treatment
- present data on cancer cell death

